IRIS
CALCAGNO, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.317
EU - Europa 5.376
AS - Asia 3.526
SA - Sud America 669
AF - Africa 624
Continente sconosciuto - Info sul continente non disponibili 393
OC - Oceania 9
Totale 16.914
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.944
RU - Federazione Russa 2.326
NL - Olanda 1.880
SG - Singapore 1.322
CN - Cina 1.008
BJ - Benin 471
BR - Brasile 420
VN - Vietnam 340
FR - Francia 339
BD - Bangladesh 308
IT - Italia 299
CA - Canada 169
DE - Germania 131
IN - India 114
HK - Hong Kong 106
GB - Regno Unito 104
MX - Messico 99
AR - Argentina 82
IE - Irlanda 63
ZA - Sudafrica 54
SE - Svezia 48
ES - Italia 41
ID - Indonesia 41
IQ - Iraq 41
CO - Colombia 34
PL - Polonia 34
TR - Turchia 32
EC - Ecuador 31
JM - Giamaica 27
CL - Cile 25
SA - Arabia Saudita 25
JP - Giappone 24
UA - Ucraina 23
VE - Venezuela 21
PT - Portogallo 19
KE - Kenya 18
BO - Bolivia 17
DZ - Algeria 16
PE - Perù 16
PK - Pakistan 16
PH - Filippine 15
MA - Marocco 14
PY - Paraguay 14
AZ - Azerbaigian 11
JO - Giordania 11
KR - Corea 11
TT - Trinidad e Tobago 11
BB - Barbados 10
EG - Egitto 10
HN - Honduras 10
AU - Australia 9
CR - Costa Rica 9
UZ - Uzbekistan 9
KZ - Kazakistan 8
RS - Serbia 8
TH - Thailandia 8
TN - Tunisia 8
TW - Taiwan 8
HU - Ungheria 7
MY - Malesia 7
NP - Nepal 7
OM - Oman 7
SY - Repubblica araba siriana 7
AE - Emirati Arabi Uniti 6
CZ - Repubblica Ceca 6
ET - Etiopia 6
NI - Nicaragua 6
SN - Senegal 6
UY - Uruguay 6
BE - Belgio 5
BG - Bulgaria 5
IL - Israele 5
LT - Lituania 5
LV - Lettonia 5
PR - Porto Rico 5
PS - Palestinian Territory 5
RO - Romania 5
GT - Guatemala 4
XK - ???statistics.table.value.countryCode.XK??? 4
BM - Bermuda 3
CH - Svizzera 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
EE - Estonia 3
FI - Finlandia 3
GY - Guiana 3
KG - Kirghizistan 3
LB - Libano 3
PA - Panama 3
AW - Aruba 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
GD - Grenada 2
GE - Georgia 2
GR - Grecia 2
KH - Cambogia 2
LC - Santa Lucia 2
LK - Sri Lanka 2
MD - Moldavia 2
Totale 16.483
Salva come PNG Salva come JPEG
Città #
Amsterdam 1.873
Council Bluffs 1.352
San Jose 614
Ashburn 564
Singapore 501
Cotonou 471
Lauterbourg 315
Columbus 233
Moscow 186
New York 181
Phoenix 156
St Louis 149
Los Angeles 136
Santa Clara 126
Ho Chi Minh City 116
Hong Kong 103
Beijing 97
Falkenstein 89
Hanoi 76
Orem 76
São Paulo 70
Dublin 59
Tianjin 59
Atlanta 55
Buffalo 48
Dallas 44
Chicago 43
Denver 43
Milan 43
Toronto 43
Brooklyn 42
Guangzhou 40
Houston 39
Jacksonville 36
Warsaw 34
Chennai 28
Montreal 28
Rome 27
Johannesburg 26
Mexico City 26
Philadelphia 26
Shanghai 25
Hangzhou 22
Rio de Janeiro 21
Las Vegas 19
Poplar 19
Stockholm 19
Tokyo 19
Kingston 16
Manchester 16
Naples 16
Milwaukee 15
Nairobi 15
Turin 15
Washington 15
Charlotte 14
Da Nang 14
Detroit 14
Miami 14
Newark 14
Quito 14
New Delhi 13
Richmond 13
Seattle 13
Shenzhen 13
Brasília 12
Cincinnati 12
Louisville 12
Minneapolis 12
Querétaro 12
Baku 11
Cleveland 11
London 11
Mumbai 11
Pittsburgh 11
Queens 11
The Bronx 11
Amman 10
Baghdad 10
Bridgetown 10
Florence 10
Haiphong 10
Medan 10
Wilmington 10
Asunción 9
Cape Town 9
Jakarta 9
Nuremberg 9
Orlando 9
San Francisco 9
Virginia Beach 9
Chandler 8
Erbil 8
Frankfurt am Main 8
Guayaquil 8
Kansas City 8
La Paz 8
La Plata 8
Lima 8
Monroe 8
Totale 9.003
Salva come PNG Salva come JPEG
Nome #
Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease 1.959
Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders 112
Coinfection with other respiratory pathogens in COVID-19 patients 107
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy 88
Seroprevalence of SARS-CoV-2 among Workers in Northern Italy 88
Post-tuberculosis lung disease: a guide for clinicians 87
A Novel HPLC-MS/MS Method for the Intracellular Quantification of the Active Triphosphate Metabolite of Remdesivir: GS-443902 84
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing 84
A noma case report: A warning message from Northern Uganda 82
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort 78
Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy 76
Antiretroviral Drug Penetration into the CNS Compartment 72
Knowledge of Sexually Transmitted Infections and HIV among People Living with HIV: Should We Be Concerned? 68
Heart failure in patients with human immunodeficiency virus: a review of the literature 68
Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients 68
Ceftriaxone cerebrospinal fluid levels in adult patients with meningoencephalitis 66
Pharmacogenetics-based Schedule Adjustment of Unboosted Atazanavir-based Regimens: 48 Weeks Results of Reyagen a Randomized and Controlled Pilot Study - PE10/14 66
Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study 66
A case of histological diagnosis of Toxoplasma gondii myositis in a person living with HIV 64
Alzheimer Dementia in People Living With HIV 63
A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients 63
New UPLC-MS/MS method for simultaneous determination of dolutegravir, elvitegravir, rilpivirine and other 14 HIV drugs in human plasma 63
Parietal resting-state EEG alpha source connectivity is associated with subcortical white matter lesions in HIV-positive people 63
Cardiovascular disease in HIV patients: from bench to bedside and backwards 62
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 62
Anti-CD20 antibody therapy for B-cell lymphomas 62
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs 62
Assessing ChatGPT's Potential in HIV Prevention Communication: A Comprehensive Evaluation of Accuracy, Completeness, and Inclusivity 62
Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States 62
Incidence and clinical features of stroke in HIV patients in HAART era: a meta-analysis 61
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 61
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 61
Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort 61
Pharmacokinetic of caspofungin in patients with invasive candidiasis 60
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 60
A Machine Learning-Derived Cardiovascular Risk Score in People with HIV: The ML-ICONA Score 60
Intrathecal production of anti-EBV Viral Capsid Antigen IgG is associated with Neurocognition and tau pathology in people with HIV 60
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 59
A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era 59
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1 59
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 58
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 58
18-fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with non-tuberculous mycobacterial infections 58
Ageing with HIV: a multidisciplinary review 58
Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial 57
Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotics Supplementation 56
Neurosymptomatic HIV-1 CSF escape is associated with replication in CNS T cells and inflammation 56
Symptomatic and Asymptomatic Neurocognitive Impairment, ART Adherence and HIV Control: A 4-Year Observational Study 56
Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders 55
Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine 55
Transient plasma viral rebound after SARS-CoV-2 vaccination in an exceptional HIV-1 elite controller woman 55
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 54
Cognitive Rehabilitation Treatment in HIV/AIDS patients with Asymptomatic Neurocognitive Impairment (ANI) and Mild Neurocognitive Disorders (MND) 54
Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses? 54
Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs: A Real-World Study 53
Cerebral white matter Hyperintensities in HIV–positive patients 53
A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment 53
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 53
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV) 53
Association between tight junction proteins and cognitive performance in untreated persons with HIV 53
A LC-MS method to quantify tenofovir urinary concentrations in treated patients 53
HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era 52
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 52
Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects 52
Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 52
Intracellular Accumulation of Tipranavir/Ritonavir 52
A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis 52
Prescription habits and drugs accessibility for the treatment of non-tuberculous mycobacteria infections in Italy: a multicentric survey from the IRENE study group 52
Primary HIV infection features colonic damage and neutrophil inflammation yet containment of microbial translocation 51
Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants 51
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 51
A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection 51
Therapeutic Drug Monitoring of Boosted Protease Inhibitors and 48-week Risk of Virological Failure 51
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients 50
Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study 50
The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? 50
Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV 50
Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens 50
Diagnosis of HIV associated Neurocognitive Disorders in Italian cohort: comparison of Clinical Rating and Deficit Score 50
Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases 49
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 49
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 49
BCGitis after Bacille Calmette-Guerin intravesical administration from two referral centers: clinical characteristics and risk factors 49
Pharmacogenetics-based Schedule Adjustment of Unboosted Atazanavir Associated with Tenofovir/Emtricitabine: A Randomized Controlled Study (REYAGEN) 49
Plasma concentration of boosted and unboosted Atazanavir are predicted by 63396C>T SNP in the PXR gene 48
Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma 48
Living with HIV and Getting Vaccinated: A Narrative Review 48
Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases 48
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 48
Plasma, Intracellular and Lymph node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study 48
Staphylococcus aureus meticillino-resistente 48
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 48
Dual β-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare 47
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir 47
Changes in Cerebrospinal Fluid, Liver and Intima-media-thickness Biomarkers in Patients with HIV-associated Neurocognitive Disorders Randomized to a Less Neurotoxic Treatment Regimen 47
Central Nervous System Disorders with Auto-Antibodies in People Living with HIV 47
Changing clinical and laboratory characteristics of Progressive Multifocal Leukoencephalopathy: a retrospective national cohort study 47
Patterns of Cerebrospinal Fluid Alzheimer’s Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition 46
Cascade of care for TB infection in persons newly diagnosed with HIV in Italy 46
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV 46
Totale 7.744
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.310
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.310
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202229 0 0 0 5 1 0 0 0 4 4 7 8
2022/202397 9 7 9 0 4 7 2 3 53 0 3 0
2023/202429 4 3 1 0 5 0 6 0 0 0 2 8
2024/202581 0 0 4 1 0 2 7 11 22 18 3 13
2025/202612.932 8 12 27 1.793 1.798 993 1.582 1.926 2.575 843 750 625
2026/20273.684 1.401 984 1.030 269 0 0 0 0 0 0 0 0
Totale 16.914